vascular endothelial growth factor Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (3)

Phase 1 (1)
Unknown (2)

Observational (2)
Interventional (1)

National Cancer Institute, Naples (1)
Shanghai Jiao Tong University School of Medicine (1)
The First Affiliated Hospital of Zhengzhou University (1)

No (3)

No (3)

Adult (18+) (3)

I am/have/had

I am/have/hadliver metastasis

I am/have/hadtumor burden

I am/have/hadneutrophil count

I am/have/hadcancer

I am/have/hadplatelet count

I am/have/hadhypertension

I am/have/hadvascular endothelial growth factor receptor 2

I am/have/hadvascular endothelial growth factor

I am/have/hadtyrosine

I am/have/hadtargeted therapy

I am/have/hadglioma

I am/have/hadEGFR

I am/have/hadwhite blood cell count

I am/have/hadrenal function

I am/have/hadpostoperative complication

I am/have/hadlymph node metastases

I am/have/hadvegf

I am/have/hadmetastasis

I am/have/hadhead and neck squamous cell carcinoma

I am/have/hadsquamous cell carcinoma of the head and neck

added new label for I am/have/had

I am looking for

I am looking forvegf

I am looking foraflibercept

I am looking forbevacizumab

I am looking forapatinib

I am looking forfluoropyrimidine

I am looking fortyrosine

I am looking forimmune checkpoint inhibitor

I am looking forcamrelizumab

I am looking forgrowth factor

I am looking foroxaliplatin

I am looking forvascular endothelial growth factor

I am looking forangiogenesis inhibitors

added new label for I am looking for

Advanced Filters

Found 3 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

For Seniors
For adults
Recruiting in 100s
Observational Study
all
Recruiting

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Apatinib, also known as YN968D1, is a small-molecule tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). This study aims to collect clinical, radiological and histopathology imaging including detailed radiological data, survival data, clinical parameters, molecular pathology and images of HE slices …

liver metastasis

vegf

metastasis

glioma

neutrophil count

0 views
19 Feb, 2024

For Seniors
For adults
Recruiting in 100s
Observational Study
all
Recruiting

Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

Furthermore, the serum levels of angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2), vascular endothelial growth factor-A and C (VEGF-A and C), stromal cell-derived factor-1 (SDF-1), platelet-derived growth factor beta (PDGF-), basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), chemokine (C-C motif) ligand 2 (CCL2), and chemokine (C-C motif) ligand 5 (CCL5) and Placental Growth …

vegf

aflibercept

bevacizumab

EGFR

fluoropyrimidine

0 views
19 Feb, 2024

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Dental/Oral Health
Recruiting

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Pre-operative inductive therapy can reduce tumor volume, increase organ retention rate, and reduce distant metastasis rate. Vascular endothelial growth factor (VEGF) receptor in head and neck squamous cell carcinoma is over-expressed and associated with disease invasion and poor prognosis.

vegf

metastasis

tumor burden

head and neck squamous cell carcinoma

squamous cell carcinoma of the head and neck

0 views
19 Feb, 2024